Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Research Areas-Other Indications-Steatohepatitis

Request The Product List ofSteatohepatitis Steatohepatitis

Steatohepatitis is one type of liver disease which can be characterized by the inflammation and fat accumulation of liver which is a part of the alcoholic liver disease. It is otherwise called as fatty liver disease.


Type：

1.Nonalcoholic Steatohepatitis(NASH)

2.Alcoholic Steatohepatitis(ASH)

Cat. No. Product Name CAS No. Information
H9317

Ervogastat

 		2186700-33-2

Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor (DGAT2i). Ervogastat alone reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH); Ervogastat combination with Clesacostat (an acetyl CoA-carboxylase inhibitor (ACCi)) can be used for the research of NASH with liver fibrosis therapy.
H9293

Clesacostat

 		1370448-25-1

Clesacostat is a potent and selective ACC inhibitor (hACC1 IC50 = 13nM; hACC@ IC50 = 9 nM);PF-0522130 selectively inhibits liver DNL in animals, while demonstrating considerable safety margins against platelet reduction in a nonhuman primate model.
H9277

CRV431

 		1383420-08-3

CRV431(Rencofilstat) is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM);CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease
H9132

Cenicriviroc Mesylate

 		497223-28-6

Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
H9131

Cenicriviroc

 		497223-25-3

Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.
H8978

Vonafexor

 		1192171-69-9

Vonafexor (EYP001) is a selective FXR agonist with anti-HBV effects.
H7394

Selonsertib

 		1448428-04-3

Selonsertib (GS-4997)?is a highly selective and potent, ATP-competetive inhibitor of ASK1 (Apoptosis Signal-regulating Kinase 1,?MAP3K5) with potential anti-inflammatory, antineoplastic and anti-fibrotic activities; orally bioavailable.
H6189

BI 1467335

 		1478364-68-9

BI 1467335 (PXS-4728A,?PXS-4728) is a potent, selective, orally active SSAO/VAP-1 (AOC3) inhibitor with IC50 of 5 nM; displays >500-fold selective for VAP-1/SSAO over all the related human amine oxidases; diminishes leukocyte rolling and adherence induced by CXCL1/KC, also inhibits the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis.
H5903

IVA-337

 		927961-18-0

IVA-337 (Lanifibranor, IVA337)) is a potent, pan PPAR agonist with EC50 of 0.92 uM, 0.53 uM and 0.18 uM for human PPARα, PPARδ and PPARγ respectively; reduces skin fibrosis in the mouse, and suppresses inflammation in vivo.
H5865

Apararenone

 		945966-46-1

Apararenone (MT-3995) is a novel potent, selective non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1